$RDHL - " Talicia® available through pharmacies nationwide."
TEL-AVIV, Israel and RALEIGH, N.C., March 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today announced that Express Scripts has added Talicia® (omeprazole magnesium, amoxicillin and rifabutin)1 to its National Preferred Formulary as a preferred brand. RedHill recently launched Talicia® in the U.S., making Talicia® available through pharmacies nationwide.
“The addition of Talicia® to Express Scripts’ National Preferred Formulary reflects the urgent need for new therapies addressing the high resistance rates of H. pylori to standard-of-care antibiotics, as highlighted by the FDA and the World Health Organization in recent years. The high resistance rates have led to the declining efficacy of current standard-of-care clarithromycin-based therapies. Talicia® has a good safety and efficacy profile that is not compromised by clarithromycin resistance,” said Rick Scruggs, Chief Commercial Officer of RedHill. “H. pylori infection is a Class I carcinogen and the strongest known risk factor for development of peptic ulcer disease and gastric cancer. The addition of Talicia® to the National Preferred Formulary will allow millions of patients unrestricted access to this important new treatment. We expect to secure additional formulary coverage in the coming weeks and months to allow more patients to benefit from Talicia®.”
Talicia® is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria to clarithromycin-based standard-of-care therapies. The high rates of H. pylori resistance to clarithromycin have led to significant rates of treatment failure with clarithromycin-based standard-of-care therapy and are a strong public health concern. Minimal to zero resistance to rifabutin, a key component of Talicia®, was detected in RedHill’s pivotal Phase 3 study.
Let break that triangle and pass 4.82-5$
“The addition of Talicia® to Express Scripts’ National Preferred Formulary reflects the urgent need for new therapies addressing the high resistance rates of H. pylori to standard-of-care antibiotics, as highlighted by the FDA and the World Health Organization in recent years. The high resistance rates have led to the declining efficacy of current standard-of-care clarithromycin-based therapies. Talicia® has a good safety and efficacy profile that is not compromised by clarithromycin resistance,” said Rick Scruggs, Chief Commercial Officer of RedHill. “H. pylori infection is a Class I carcinogen and the strongest known risk factor for development of peptic ulcer disease and gastric cancer. The addition of Talicia® to the National Preferred Formulary will allow millions of patients unrestricted access to this important new treatment. We expect to secure additional formulary coverage in the coming weeks and months to allow more patients to benefit from Talicia®.”
Talicia® is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria to clarithromycin-based standard-of-care therapies. The high rates of H. pylori resistance to clarithromycin have led to significant rates of treatment failure with clarithromycin-based standard-of-care therapy and are a strong public health concern. Minimal to zero resistance to rifabutin, a key component of Talicia®, was detected in RedHill’s pivotal Phase 3 study.
Let break that triangle and pass 4.82-5$